MAP2K7 and acute myeloid leukemia: However, inhibitors of mitogen-activated protein kinase kinase (MEK), a key protein of the RAS-MAPK-ERK pathway, have failed to show meaningful anti-leukemic activity in several clinical studies of either RAS-mutant and RAS wild-type AML [141,142,143].